Company Filing History:
Years Active: 2004
Title: Nina Bhardwai: Innovator in Cellular Immunity
Introduction
Nina Bhardwai is a prominent inventor based in Montclair, NJ (US). She has made significant contributions to the field of cellular immunity, particularly in the context of immune-privileged antigens. Her work has implications for both diagnostics and therapeutic treatments in oncology.
Latest Patents
Nina holds a patent titled "Methods and agents for the detection and modulation of cellular immunity to immune privileged antigens." This patent addresses the role of cellular immune responses in the etiology of paraneoplastic syndromes and tumor immunity. It provides diagnostic and therapeutic methods for detecting paraneoplastic antigen-specific cells, enhancing tumor immunity by increasing the population of cytotoxic T lymphocytes (CTLs), and suppressing cellular immunity to treat paraneoplastic syndromes. The methods described utilize immune-privileged antigens or their peptides for the detection of memory and cytotoxic T lymphocytes. Enhanced CTL production is achieved by stimulating antigen-presenting cells in vitro with immune-privileged antigens, with or without further exposure to T lymphocytes, prior to reintroduction into the patient. Additionally, the patent discusses the use of agents that suppress the cellular response to non-tumor cells expressing immune-privileged antigens, as well as anti-cytokine therapy to limit the expression of paraneoplastic antigens by non-tumor cells.
Career Highlights
Nina is affiliated with The Rockefeller University, where she continues her research and innovation in cellular immunity. Her work has garnered attention for its potential to improve cancer diagnostics and treatments.
Collaborations
Nina has collaborated with notable colleagues, including Robert Darnell and Matthew L Albert. These collaborations have furthered her research and contributed to advancements in the field.
Conclusion
Nina Bhardwai is a trailblazer in the realm of cellular immunity, with a focus on immune-privileged antigens. Her innovative patent and ongoing research at The Rockefeller University highlight her commitment to advancing medical science and improving patient outcomes.